Pancreatic Cancer Research

ResearcherKyushu UniversityActive in the last 2 years

Yoshinao Oda

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9636-1182; OpenAlex author ID A5049884976. Sources: OpenAlex.

Their work

Papers
61 (first author 0, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
127
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: 7 papers · 2015: 5 papers · 2016: 6 papers · 2017: 6 papers · 2018: 2 papers · 2019: 5 papers · 2020: 6 papers · 2021: 4 papers · 2022: 2 papers · 2023: 5 papers · 2024: 7 papers · 2025: 3 papers · 2026: 1 paper

Papers 50 of 61

  1. S100A6 expression in resected specimens predicts lymph node metastasis in small pancreatic ductal adenocarcinoma: A retrospective cohort study. Co-author DOI 10.1016/j.surg.2026.110423↗
  2. Prognostic Significance of Desmoplastic Reaction Classification and Its Association With Stromal Biomarkers in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1016/j.modpat.2025.100865↗
  3. uPAR expression in M-MDSCs under high LDHA activity in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-025-29823-4↗
  4. Risk Factors for Early Recurrence of Resectable Pancreatic Cancer. Co-author DOI 10.21873/anticanres.17792↗
  5. MicroRNA-20a in extracellular vesicles derived from duodenal fluid is a possible biomarker for pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/deo2.333↗
  6. Immature stroma and high infiltration of CD15+ cells are predictive markers of poor prognosis in different subsets of patients with pancreatic cancer. Last author DOI 10.1111/cas.16060↗
  7. Combined Autophagy Inhibition and Dendritic Cell Recruitment Induces Antitumor Immunity and Enhances Immune Checkpoint Blockade Sensitivity in Pancreatic Cance… Co-author DOI 10.1158/0008-5472.can-24-0830↗
  8. TAK1 Promotes an Immunosuppressive Tumor Microenvironment through Cancer-Associated Fibroblast Phenotypic Conversion in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-24-1004↗
  9. Blockade of histamine receptor H1 augments immune checkpoint therapy by enhancing MHC-I expression in pancreatic cancer cells. Co-author DOI 10.1186/s13046-024-03060-5↗
  10. Tumor-associated neutrophils upregulate Nectin2 expression, creating the immunosuppressive microenvironment in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-024-03178-6↗
  11. Dynamic glycolytic reprogramming effects on dendritic cells in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13046-024-03192-8↗
  12. Involvement of angiogenesis in cancer-associated acinar-to-ductal metaplasia lesion of pancreatic cancer invasive front. Co-author DOI 10.1007/s00432-022-04554-5↗
  13. Clinical Implications of FDG-PET in Pancreatic Ductal Adenocarcinoma Patients Treated with Neoadjuvant Therapy. Co-author DOI 10.1007/s11605-023-05591-2↗
  14. Extracellular volume fraction determined by dual-layer spectral detector CT: Possible role in predicting the efficacy of preoperative neoadjuvant chemotherapy … Co-author DOI 10.1016/j.ejrad.2023.110756↗
  15. Intratumor Fusobacterium nucleatum promotes the progression of pancreatic cancer via the CXCL1-CXCR2 axis. Co-author DOI 10.1111/cas.15901↗
  16. C4orf47 contributes to the dormancy of pancreatic cancer under hypoxic conditions. Co-author DOI 10.7150/jca.78993↗
  17. Prediction of pathological response to preoperative chemotherapy for pancreatic ductal adenocarcinoma using 2-[18F]-fluoro-2-deoxy-d-glucose positron-emission … Co-author DOI 10.1016/j.crad.2022.03.001↗
  18. Subtypes in pancreatic ductal adenocarcinoma based on niche factor dependency show distinct drug treatment responses. Co-author DOI 10.1186/s13046-022-02301-9↗
  19. Collision of a pancreatic ductal adenocarcinoma and a pancreatic neuroendocrine tumor associated with multiple endocrine neoplasm type 1. Co-author DOI 10.1007/s12328-020-01234-0↗
  20. Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy. Co-author DOI 10.1016/j.cell.2021.07.020↗
  21. A deep learning model to detect pancreatic ductal adenocarcinoma on endoscopic ultrasound-guided fine-needle biopsy. Co-author DOI 10.1038/s41598-021-87748-0↗
  22. Impact of Capicua on Pancreatic Cancer Progression. Co-author DOI 10.1245/s10434-020-09339-z↗
  23. Is remnant pancreatic cancer after pancreatic resection more frequent in early-stage pancreatic cancer than in advanced-stage cancer? Co-author DOI 10.1002/ags3.12340↗
  24. Chronic inflammatory changes and oxidative stress in the background of "pancreatic ductal adenocarcinoma concomitant with intraductal papillary mucinous neopla… Last author DOI 10.1007/s00428-020-02844-2↗
  25. Mitochondrial expression of the DNA repair enzyme OGG1 improves the prognosis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2020.07.011↗
  26. Concomitant Intraductal Papillary Mucinous Neoplasm in Pancreatic Ductal Adenocarcinoma Is an Independent Predictive Factor for the Occurrence of New Cancer in… Last author DOI 10.1097/sla.0000000000003060↗
  27. Necroptosis in pancreatic cancer promotes cancer cell migration and invasion by release of CXCL5. Co-author DOI 10.1371/journal.pone.0228015↗
  28. FAM115C could be a novel tumor suppressor associated with prolonged survival in pancreatic cancer patients. Last author DOI 10.7150/jca.38399↗
  29. CD110 promotes pancreatic cancer progression and its expression is correlated with poor prognosis. Co-author DOI 10.1007/s00432-019-02860-z↗
  30. Cancer-associated acinar-to-ductal metaplasia within the invasive front of pancreatic cancer contributes to local invasion. Co-author DOI 10.1016/j.canlet.2018.12.005↗
  31. IFN-γ Promotes Epithelial-Mesenchymal Transition and the Expression of PD-L1 in Pancreatic Cancer. Co-author DOI 10.1016/j.jss.2019.02.038↗
  32. Pancreatic Juice Exosomal MicroRNAs as Biomarkers for Detection of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-019-07269-z↗
  33. Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer Potentially Improves Survival and Facilitates Surgery. Co-author DOI 10.1245/s10434-019-07309-8↗
  34. Surveillance of patients with intraductal papillary mucinous neoplasm with and without pancreatectomy with special reference to the incidence of concomitant pa… Co-author DOI 10.1016/j.surg.2017.09.040↗
  35. Prognostic Value of Preoperative Nutritional and Immunological Factors in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-018-6761-6↗
  36. The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer. Co-author DOI 10.1002/cam4.1087↗
  37. Clinical importance of intraoperative peritoneal cytology in patients with pancreatic cancer. Co-author DOI 10.1016/j.surg.2016.10.035↗
  38. Autophagy Is Required for Activation of Pancreatic Stellate Cells, Associated With Pancreatic Cancer Progression and Promotes Growth of Pancreatic Tumors in Mi… Co-author DOI 10.1053/j.gastro.2017.01.010↗
  39. S100P in Duodenal Fluid Is a Useful Diagnostic Marker for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000940↗
  40. Extra-pancreatic invasion induces lipolytic and fibrotic changes in the adipose microenvironment, with released fatty acids enhancing the invasiveness of pancr… Co-author DOI 10.18632/oncotarget.15430↗
  41. Degree of desmoplasia in metastatic lymph node lesions is associated with lesion size and poor prognosis in pancreatic cancer patients. Co-author DOI 10.3892/ol.2017.6549↗
  42. Nuclear expression of Y-box binding protein-1 is associated with poor prognosis in patients with pancreatic cancer and its knockdown inhibits tumor growth and … Co-author DOI 10.1002/ijc.30075↗
  43. CD146 attenuation in cancer-associated fibroblasts promotes pancreatic cancer progression. Co-author DOI 10.1002/mc.22409↗
  44. Comparison of Surgical Outcomes Between Radical Antegrade Modular Pancreatosplenectomy (RAMPS) and Standard Retrograde Pancreatosplenectomy (SPRS) for Left-Sid… Co-author DOI 10.1007/s00268-016-3526-x↗
  45. Hypoxic stellate cells of pancreatic cancer stroma regulate extracellular matrix fiber organization and cancer cell motility. Co-author DOI 10.1016/j.canlet.2016.01.016↗
  46. Suppression of CD51 in pancreatic stellate cells inhibits tumor growth by reducing stroma and altering tumor-stromal interaction in pancreatic cancer. Co-author DOI 10.3892/ijo.2016.3374↗
  47. Overexpression of microRNA-5100 decreases the aggressive phenotype of pancreatic cancer cells by targeting PODXL. Co-author DOI 10.3892/ijo.2016.3389↗
  48. Anterior gradient 2 downregulation in a subset of pancreatic ductal adenocarcinoma is a prognostic factor indicative of epithelial-mesenchymal transition. Last author DOI 10.1038/labinvest.2014.138↗
  49. Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000000258↗
  50. Predictors and Diagnostic Strategies for Early-Stage Pancreatic Ductal Adenocarcinoma: A Retrospective Study. Co-author DOI 10.1097/mpa.0000000000000393↗

Closest collaborators

The 25 strongest of 127 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kohei Nakata · 30 shared papers, 2011–2026 · strength 3.98
  2. Kenoki Ohuchida · 34 shared papers, 2011–2026 · strength 3.41
  3. Masafumi Nakamura · 27 shared papers, 2014–2025 · strength 2.88
  4. Takao Ohtsuka · 32 shared papers, 2013–2025 · strength 2.26
  5. Naoki Ikenaga · 14 shared papers, 2011–2026 · strength 2.15
  6. Toshiya Abe · 17 shared papers, 2016–2026 · strength 2.05
  7. Yoshihiro Miyasaka · 22 shared papers, 2015–2025 · strength 1.75
  8. Noboru Ideno · 15 shared papers, 2013–2026 · strength 1.70
  9. Chika Iwamoto · 13 shared papers, 2017–2025 · strength 1.67
  10. Koji Shindo · 14 shared papers, 2013–2025 · strength 1.48
  11. Hideya Onishi · 7 shared papers, 2016–2026 · strength 1.01
  12. Masafumi Nakamura · 10 shared papers, 2016–2024 · strength 1.00
  13. Chikanori Tsutsumi · 5 shared papers, 2024–2025 · strength 0.92
  14. Yasuhisa Mori · 10 shared papers, 2014–2025 · strength 0.87
  15. Koki Oyama · 5 shared papers, 2023–2024 · strength 0.82
  16. Masataka Hayashi · 5 shared papers, 2023–2024 · strength 0.79
  17. Masao Tanaka · 17 shared papers, 2011–2017 · strength 0.72
  18. Kousei Ishigami · 4 shared papers, 2022–2025 · strength 0.70
  19. Yusuke Mizuuchi · 8 shared papers, 2015–2025 · strength 0.65
  20. Tomohiko Shinkawa · 4 shared papers, 2022–2024 · strength 0.64
  21. Kazuhiro Koikawa · 7 shared papers, 2017–2024 · strength 0.64
  22. Haizhen Luo · 4 shared papers, 2023–2024 · strength 0.63
  23. Pingshan Zhong · 4 shared papers, 2023–2024 · strength 0.63
  24. Ryota Matsuda · 6 shared papers, 2019–2021 · strength 0.62
  25. Masafumi Nakamura · 3 shared papers, 2024–2025 · strength 0.61

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.